Healx Bags $56M to Advance Affordable, AI-Based Orphan Drugs

Healx Bags $56M to Advance Affordable, AI-Based Orphan Drugs

Source: 
Xconomy
snippet: 

Atomico, a European venture capital firm, has helped persuade Cambridge, UK-based Healx to return to the capital market a year earlier than anticipated. The biotech has just raised $56 million in Series B funding to bankroll its mission to use AI and machine learning to create affordable rare disease treatments.